Innoviva, Inc.

$13.86
INVA - NASDAQ
Dividend yield
Average yield for past twelve months.
-
P/E ratio
-
Payout ratio
Proportion of net income paid out as dividends to shareholders
-
Yearly
Company profitability (EPS)
-
past 12 months
CASH payout ratio
Innoviva, Inc. last quarter cash income being paid in the form of dividends.
Last quarter
Become our supporter to unlock all data!
Stock volatility (Beta)
See how volatile INVA stock is compared to other dividend stocks and to its sector
past 12 months
Become our supporter to unlock all data!
Company debt level
How much debt Innoviva, Inc. have in comparison to other dividend stocks
Become our supporter to unlock all data!
Innoviva, Inc. description

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P.

Roy Vagelos, Mathai Mammen, and George M.

Company profile
Market cap
Small (1.40B)
Company CEO
Geoffrey L. Hulme
Price history Innoviva, Inc.
Loading price stock history...
INVA dividends payouts
Similar stocks as Innoviva, Inc.